Published in J Natl Cancer Inst on June 01, 1957
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer (1976) 4.76
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
The use of immunologically competent cells in the treatment of cancer: experiments with a transplantable mouse tumour. Br J Cancer (1962) 3.10
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 2.96
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94
Immunity to malignant disease in man. Br Med J (1969) 2.88
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47
Impact of gas(less) laparoscopy and laparotomy on peritoneal tumor growth and abdominal wall metastases. Ann Surg (1996) 2.45
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med (1990) 2.41
Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J (1993) 2.25
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A (1968) 2.12
Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol (2010) 2.02
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med (1983) 1.89
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med (1981) 1.77
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med (1989) 1.76
An experimental method for comparing treatments of intact malignant tumours in animals and its application to the use of oxygen in radiotherapy. Br J Cancer (1960) 1.68
Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg (1970) 1.68
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer (1969) 1.59
Cancer immunotherapy. Can Med Assoc J (1979) 1.54
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
High-frequency cotransfer of the transformed phenotype and a tumor-specific transplantation antigen by DNA from the 3-methylcholanthrene-induced Meth A sarcoma of BALB/c mice. Proc Natl Acad Sci U S A (1981) 1.38
Natural endogenous adjuvants. Springer Semin Immunopathol (2004) 1.34
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med (2005) 1.31
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol (1991) 1.31
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med (2000) 1.31
Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30
Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes. Ann Surg (1966) 1.29
Chromosome assignment of the tumor-specific antigen of a 3-methylcholanthrene-induced mouse sarcoma. J Exp Med (1981) 1.29
Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med (1986) 1.27
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A (1996) 1.27
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
Quantitative studies of translymphnodal passage of tumour cells naturally disseminated from a non immunogenic murine squamous carcinoma. Br J Cancer (1975) 1.26
Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med (1983) 1.26
Some aspects of the problem of immunity against transplanted and spontaneous tumors. Bacteriol Rev (1962) 1.26
Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res (2011) 1.24
Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci U S A (1985) 1.23
Immunogenic properties of rat hepatoma subcellular fractions. Br J Cancer (1974) 1.20
Acquired tolerance, autoantibodies and cancer. Can Med Assoc J (1962) 1.20
Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother (2013) 1.19
Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol (2011) 1.17
Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer (1973) 1.17
Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci U S A (1997) 1.15
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Enhancement of syngeneic murine tumour transplantability by whole body irradiation--a non-immunological phenomenon. Br J Cancer (1975) 1.13
Purification and biochemical properties of tumor-associated transplantation antigens from methylcholanthrene-induced murine sarcomas. Proc Natl Acad Sci U S A (1982) 1.13
Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts. J Exp Med (1966) 1.12
Specificity in cancer immunotherapy. Semin Immunol (2008) 1.11
5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors. Proc Natl Acad Sci U S A (1987) 1.10
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother (2010) 1.10
Failure of specific active immunotherapy in lung cancer. Br J Cancer (1981) 1.09
A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med (1996) 1.09
Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methylcholanthrene. J Exp Med (1979) 1.08
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A (1982) 1.07
Survival in bronchial carcinoma. Tumour remaining in the bronchial stump following resection. Ann R Coll Surg Engl (1972) 1.06
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med (1994) 1.05
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med (1984) 1.04
Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med (1990) 1.03
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A (2001) 1.03
Preparation of a "chemical vaccine" against tumor progression. Proc Natl Acad Sci U S A (1971) 1.03
Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera. Proc Natl Acad Sci U S A (1979) 1.03
Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med (1981) 1.02
Effect of single and fractionated doses of x-rays on radiocurability of solid Ehrlich tumour and tissue reactions in vivo, for different oxygen tensions. Br J Cancer (1962) 1.01
T-cell antigens in cancer. Proc Natl Acad Sci U S A (1994) 1.01
Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A (1982) 1.00
Premalignant lesions as targets for cancer vaccines. J Exp Med (2003) 0.99
Autoimmune reactions in uveal melanoma. Br J Ophthalmol (1971) 0.99
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol (1995) 0.99
Hsp90 and client protein maturation. Methods Mol Biol (2011) 0.98
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev (2013) 0.95
Prolonged administration of antithymocyte serum in mice. II. Histopathological investigation. Clin Exp Immunol (1971) 0.94
In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors. J Exp Med (1973) 0.94
An immune reaction may be necessary for cancer development. Theor Biol Med Model (2006) 0.94
Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med (1996) 0.93
The growth of cells in vivo in diffusion chambers. II. The role of cells in the destruction of homografts in mice. J Natl Cancer Inst (1955) 3.57
Growth of cells in vivo in diffusion chambers. I. Survival of homografts in immunized mice. J Natl Cancer Inst (1954) 3.47
Studies on tissue homotransplantation in mice, using diffusion-chamber methods. Ann N Y Acad Sci (1957) 2.75
Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst (1955) 2.16
FUNCTION OF DEPRESSED IMMUNOLOGIC REACTIVITY DURING CARCINOGENESIS. J Natl Cancer Inst (1963) 1.75
Specific homograft tolerance induced by successive matings and implications concerning choriocarcinoma. J Natl Cancer Inst (1960) 1.35
A CLONAL SELECTION THEORY OF CHEMICAL CARCINOGENESIS. J Natl Cancer Inst (1964) 1.28
Tumor-specific antigens and the homograft reaction. Am J Surg (1963) 1.26
DIFFERENTIAL TOXICITY RESPONSE OF NORMAL AND NEOPLASTIC CELLS IN VITRO TO 3,4-BENZOPYRENE AND 3-METHYLCHOLANTHRENE. Br J Cancer (1964) 1.23
Tumors and hyperplastic nodules in transplanted mammary glands. J Natl Cancer Inst (1953) 1.17
Factors influencing tumor distribution among the mammary glands of the mouse. J Natl Cancer Inst (1954) 1.16
TUMOR SPECIFIC IMMUNITY TO NONVIRAL TUMORS. Proc Can Cancer Conf (1963) 1.14
The diffusion-chamber technique applied to a study of the nature of homograft resistance. J Natl Cancer Inst (1954) 1.04
The influence of sex on isologous skin grafting in the mouse. J Natl Cancer Inst (1956) 0.91
Fate of skin homografts in x-irradiated mice treated with homologous marrow. J Natl Cancer Inst (1957) 0.89
Lack of immunizing capacity of homologous cells within diffusion chambers. J Natl Cancer Inst (1956) 0.84
Tumor tissue as a site for interstrain tumor transplantation in mice. J Natl Cancer Inst (1953) 0.81
ROLE OF THE FIBROUS CAPSULE IN CARCINOGENESIS BY PLASTIC FILM. Nature (1965) 0.81
Failure of immunization against tumorigenesis. J Natl Cancer Inst (1961) 0.81
Number of mouse histocompatibility genes involved in skin grafting from strain BALB/cAn to strain DBA/2. J Natl Cancer Inst (1958) 0.80
A comparison between heterozygous and homozygous skin homografts. J Natl Cancer Inst (1954) 0.80
Skin homograft tolerance produced by repeated grafting. Transplant Bull (1961) 0.78
The immunity-inhibiting role of the spleen and the effect of dosage and route of antigen administration in a homograft reaction. Bull Soc Int Chir (1959) 0.77
Transfer of the mammary tumor milk agent from implant to host. J Natl Cancer Inst (1952) 0.77
Mobile resistance factor in acquired immunity to homologous tissue transplantation. J Natl Cancer Inst (1953) 0.75
Mobility and site of production of homograft resistance factor. J Natl Cancer Inst (1954) 0.75
Lack of intrinsic incompatibility between tissues of different genetic origin. J Natl Cancer Inst (1953) 0.75
Note on the lack of progressive growth of metastatic mammary carcinoma transplanted subcutaneously into foreign strains of mice. J Natl Cancer Inst (1950) 0.75